Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD urged to overturn decision on flunixin
Flunixin is a common analgesic used in horses with colic

Product suspended over potential risk to humans

Leading equine veterinary association BEVA is urging the Veterinary Medicines Directorate (VMD) to overturn its decision to suspend the sale of flunixin.

Flunixin is a common analgesic used in horses with colic, as well as for those undergoing surgery and other conditions. On Thursday (26 July), the VMD suspended the product after the Committee for Medicinal Products for Veterinary Use (CVMP) said that a solvent in the injectable formulation - diethanolamine - could pose a risk to humans.

Now BEVA is calling on the VMD to overturn this decision in horses not destined for the human food chain, to reduce the potential impact on equine welfare. It argues that the decision had been made without warning or consultation with the veterinary profession.

“BEVA is fully supportive of all attempts to promote food safety, however, flunixin is widely viewed as the gold-standard painkiller in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic,” said BEVA president Jonathan Pycock.

“BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue.

“BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”

Used widely throughout the veterinary industry, flunixin is the only medicine licensed for the treatment of sepsis. BEVA states that no recall notices have been issued and therefore veterinary surgeons may continue to prescribe medicines that are in stock.

A disruption to the supply chain, however, could lead to shortages of this medicine in clinical practic, it said. 

Image (C) Redwings Horse Sanctuary

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.